Brief: Amneal Announces BLA Submission Of Biosimilar Candidate To Xolair® (Omalizumab)
26/09/2025 13:05
Sept 26 (Reuters) - Amneal Pharmaceuticals Inc AMRX.O: AMNEAL ANNOUNCES BLA SUBMISSION OF BIOSIMILAR CANDIDATE TO XOLAIR® (OMALIZUMAB) AMNEAL PHARMACEUTICALS INC - CO EXPECTS $22.5 MILLION RESEARCH AND DEVELOPMENT CHARGE IN QTRLY 2025 Source text: ID:nGNX67cWml Further company coverage: AMRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amneal Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-3M Company, Constellation Energy, Metropolitan Bank Holding
US FDA is working with manufacturers to boost estrogen patch supply amid access concerns (updated)
U.S. RESEARCH ROUNDUP- Intuit, MongoDB, Zscaler
U.S. STOCKS ON THE MOVE-Mastercard, Yum, Equinix
Amneal Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary